FM’s intent to give relief to patients will be realised more with GST exemption and will make a huge impact, considering that in India 80% of healthcare expenses are out of pocket, writes Biocon ...

In today's rapidly changing business environment, leadership and values are crucial to achieving growth. The stories of ...

A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

Biocon Ltd founder and executive chairperson Kiran Mazumdar-Shaw tweeted the death of Menezes on her X account, calling him "a wonderful and wise colleague at MIT Corporation who will be missed for ...

Following the presentation of the Union Budget 2025, several prominent industry leaders have shared their reactions, offering ...

Therapy will cost Rs 35 to 50 lakh. India sees around 1.20 lakh new blood cancer cases and over 70,000 deaths annually from ...

The Union Budget 2025-26 garnered varied reactions from leaders in Rajasthan, with Deputy Chief Minister Diya Kumari calling ...

The company that developed the drug is a gene and cell therapy startup backed by Biocon founder Kiran Mazumdar Shaw and ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

District daycare centres will decentralize cancer care, but India needs thousands more oncologists, specialist nurses and ...

India is seeing a significant rise in women among its wealthiest individuals. Forbes' Real-Time Billionaires ranking for ...